A randomized, placebo-controlled study of the efficacy and safety of fixed-dose brexpiprazole 2 mg/d as adjunctive treatment of adults with major depressive disorder / Mary Hobart en The Journal of Clinical Psychiatry, Año 2018 - Vol. 79 - No.4 (Julio - Agosto)

Público ISBD [artículo]  inThe Journal of Clinical Psychiatry > Año 2018 - Vol. 79 - No.4 (Julio - Agosto) . - pp. 11-17 Título : A randomized, placebo-controlled study of the efficacy and safety of fixed-dose brexpiprazole 2 mg/d as adjunctive treatment of adults with major depressive disorder Tipo de documento: texto impreso Autores: Mary Hobart, Autor ; Aleksandar Skuban, Autor ; Peter Zhang, Autor Fecha de publicación: 2018 Artículo en la página: pp. 11-17 Idioma : Inglés (eng) Palabras clave: Brexpiprazole, Placebo, Trastorno depresivo mayor, Antidepresivos. Resumen: To assess the efficacy, safety, and tolerability of brexpiprazole as adjunct to antidepressant treatment (ADT) in adults with major depressive disorder (MDD) and inadequate response to ADTs. Link: ./index.php?lvl=notice_display&id=13459 [artículo] A randomized, placebo-controlled study of the efficacy and safety of fixed-dose brexpiprazole 2 mg/d as adjunctive treatment of adults with major depressive disorder [texto impreso] / Mary Hobart, Autor ; Aleksandar Skuban, Autor ; Peter Zhang, Autor . - 2018 . - pp. 11-17. Idioma : Inglés (eng) in The Journal of Clinical Psychiatry > Año 2018 - Vol. 79 - No.4 (Julio - Agosto) . - pp. 11-17 Palabras clave: Brexpiprazole, Placebo, Trastorno depresivo mayor, Antidepresivos. Resumen: To assess the efficacy, safety, and tolerability of brexpiprazole as adjunct to antidepressant treatment (ADT) in adults with major depressive disorder (MDD) and inadequate response to ADTs. Link: ./index.php?lvl=notice_display&id=13459

---

1 (1 - 1 / 1)